Journal of Pain and Symptom Management
Volume 40, Issue 2 , Pages 256-265 , August 2010

Using Vital Sign Flow Sheets Can Help to Identify Neoplastic Fever and Other Possible Causes in Oncology Patients: A Retrospective Observational Study

,Accepted 19 January 2010.

References 

  1. Rolston KV. Neoplastic fever: all who shiver are not infected. Support Care Cancer. 2005;13:863–864
  2. Zell JA, Chang JC. Neoplastic fever: a neglected paraneoplastic syndrome. Support Care Cancer. 2005;13:870–877
  3. Luft FC, Rissing JP, White A, Brooks GF. Infections or neoplasm as causes of prolonged fever in cancer patients. Am J Med Sci. 1976;272:65–74
  4. Penel N, Degardin M, Frippiat F, et al. Are there criteria for the diagnosis of paraneoplastic fever?. Rev Med Interne. 2000;21:684–692
  5. Penel N, Fournier C, Degardin M, Guyen MN. Fever and solid tumor: diagnostic value of procalcitonin and C-reactive protein. Rev Med Interne. 2001;22:706–714
  6. Kallio R, Bloigu A, Surcel HM, et al. C-reactive protein and erythrocyte sedimentation rate in differential diagnosis between infections and neoplastic fever in patients with solid tumours and lymphomas. Support Care Cancer. 2001;9:124–128
  7. Penel N, Fournier C, Clisant S, et al. Causes of fever and value of C-reactive protein and procalcitonin in differentiating infections from paraneoplastic fever. Support Care Cancer. 2004;2:593–598
  8. Chang JC, Gross HM. Neoplastic fever responds to the treatment of an adequate dose of naproxen. J Clin Oncol. 1985;3:552–558
  9. Chang JC, Gross HM. Utility of naproxen in the differential diagnosis of fever of undetermined origin in patients with cancer. Am J Med. 1984;76:597–603
  10. Chang JC. Antipyretic effect of naproxen and corticosteroids on neoplastic fever. J Pain Symptom Manage. 1988;3:141–144
  11. Economos K, Lucci JA, Richardson B, Yazigi R, Miller DS. The effect of naproxen on fever in patients with advanced gynecologic malignancies. Gynecol Oncol. 1995;56:250–254
  12. Tsavaris N, Zinelis A, Karabelis A, et al. A randomized trial of the effect of three non-steroid anti-inflammatory agents in ameliorating cancer-induced fever. J Intern Med. 1990;228:451–455
  13. Johnson M. Neoplastic fever. Palliat Med. 1996;10:217–224
  14. Vanderschueren S, Knockaert DC, Peetermans WE, Bobbaers HJ. Lack of value of the naproxen test in the differential diagnosis of prolonged febrile illnesses. Am J Med. 2003;115:572–575
  15. Cador-Rousseau B, Cazalets-Lacoste C, Grosbois B. Intermittent fever of neoplastic origin. Rev Prat. 2002;52:145–148
  16. Le Moing V, Leport C. Intermittent fever of infectious origin. Rev Prat. 2002;52:139–144
  17. Hachulla E. Symptomatic intermittent fever of inflammatory diseases. Rev Prat. 2002;52:160–166
  18. Goto M, Kayama H, Yakahashi O, Fukui T. A retrospective review of 226 hospitalized patients with fever. Intern Med. 2007;46:17–22
  19. Tabor PA. Drug-induced fever. Drug Intell Clin Pharm. 1986;20:413–420
  20. Dinarello CA, Bunn PA. Fever. Semin Oncol. 1997;24:288–298
  21. Liaw CC, Chen JS, Wang CH, Chang HK, Huang JS. Tumor fever in patients with nasopharyngeal carcinoma: clinical experience of 67 patients. Am J Clin Oncol. 1998;21:422–425
  22. Perdiz P, Wacher N, Laredo-Sanchez F, et al. Circadian variation of human acute phase response. Arch Med Res. 1996;27:157–163
  23. Baranowski M, Muc-Wierzgon M, Madej K, Wierzgon J, Zubelewicz B. The estimation of endogenous tumor necrosis factor alpha and cortisol levels in serum in advanced neoplasm. J Exp Clin Cancer Res. 1999;18:241–245
  24. Zubelewicz-Szkodzinska B, Muc-Wierzgon M, Wierzgon J, Brodziak A. Dynamics of circadian fluctuations in serum concentration of cortisol and TNF-alpha soluble receptors in gastrointestinal cancer patients. Oncol Rep. 2001;8:207–212
  25. Rich T, Innominato PF, Boerner J, et al. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res. 2005;11:1757–1764
  26. Lissoni P, Brivio P, Fumagalli L, et al. Immune and endocrine mechanisms of advanced cancer-related hypercortisolemia. In Vivo. 2007;21:647–650
  27. Miller AH, Ancoli-Israel S, Bower JE, et al. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol. 2008;26:971–982
  28. Schilling JD, Mulvey MA, Vincent CD, et al. Bacterial invasion augments epithelial cytokine responses to Escherichia coli through a lipopolysaccharide-dependent mechanism. J Immunol. 2001;166:1148–1155
  29. Munford RS. Sepsis and septic shock. In:  Braunwald E,  Fauci AS,  Kasper DL, et al. editor. Harrison's principles of internal medicine. 15th ed.. New York: McGraw Hill; 2001;p. 799–804
  30. Dong G, Chen Z, Kayo T, et al. The host environment promotes the constitutive activation of nuclear factor-kappaB and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma. Cancer Res. 1999;59:3495–3504
  31. Wood LJ, Nail LM, Gilster A, Elsea CR. Cancer chemotherapy-related symptoms: evidence to suggest a role for proinflammatory cytokines. Oncol Nurs Forum. 2006;33:535–542
  32. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009;8:33–40
  33. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene. 2004;23:9247–9258

PII: S0885-3924(10)00328-3

doi: 10.1016/j.jpainsymman.2010.01.015

Journal of Pain and Symptom Management
Volume 40, Issue 2 , Pages 256-265 , August 2010

Article Tools

* Image Usage & Resolution